Waldencast plc Regains Nasdaq Compliance

TL;DR

Waldencast is back in Nasdaq's good graces after fixing its low stock price issue.

AI Summary

Waldencast plc announced on March 21, 2024, that it has regained compliance with Nasdaq's minimum bid price requirement. The company had previously received a deficiency notice from Nasdaq on January 19, 2024, due to its stock price falling below $1.00 per share. Waldencast has taken steps to address this issue and is now in good standing with the exchange.

Why It Matters

Regaining compliance with Nasdaq requirements is crucial for Waldencast plc as it allows the company to remain listed on the exchange, avoiding delisting and maintaining investor confidence.

Risk Assessment

Risk Level: medium — While regaining compliance is positive, the underlying reasons for the low stock price and the company's ability to sustain compliance remain key concerns.

Key Numbers

• $1.00 — Minimum Bid Price (The minimum bid price requirement set by Nasdaq that Waldencast plc had fallen below.)

Key Players & Entities

• Waldencast plc (company) — The company filing the report and regaining compliance.
• Nasdaq (company) — The stock exchange where Waldencast plc is listed and whose requirements were met.
• March 21, 2024 (date) — The date Waldencast plc received formal notification of regaining compliance.
• January 19, 2024 (date) — The date Waldencast plc received the initial deficiency notice from Nasdaq.

FAQ

Filing Documents

• wald_6-kxnasdaqcomplianced.htm (6-K) — 22KB
• wald_991xnasdaqcomplianced.htm (EX-99.1) — 13KB
• image.jpg (GRAPHIC) — 5KB
• 0001840199-24-000020.txt ( ) — 43KB

Forward-Looking Statements

Forward-Looking Statements These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the control of the Company, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements, including, among others (i) the inability to recognize the anticipated benefits of the business combination with Obagi Skincare and Milk Makeup, (ii) failure by the Company to maintain compliance with Nasdaq's Periodic Filing Rule , including during the one-year Nasdaq monitoring period, which may result in the Company's securities being delisted from Nasdaq, (iii) the ability of the Company to file required financial results in a timely manner, (iv) the Company's ability to successfully remediate the material weaknesses in the Company's internal control over financial reporting, (v) the potential for delisting, legal proceedings or government investigations or enforcement actions, including those relating to the subject of the Audit Committee (the "Audit Committee") of the Company's Board of Directors' review or inability to finalize financial results in a timely manner, (vi) the Company's ability to obtain additional waivers from the Administrative Agent and the lenders under its credit facilities for any co

View Full Filing

View this 6-K filing on SEC EDGAR